A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pemigatinib (Primary)
Indications Lymphoid leukaemia; Lymphoma; Myeloid leukaemia
Focus Registrational; Therapeutic Use
Acronyms FIGHT-203
Sponsors Incyte Corporation

Most Recent Events

20 Sep 2024 Planned End Date changed from 31 Jul 2024 to 29 Oct 2024.
20 Sep 2024 Planned primary completion date changed from 31 Jul 2024 to 29 Oct 2024.
14 May 2024 According to Incyte media release, data from this trial will be presented at the European Hematology Association 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight